Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

Michio Ozeki; Akifumi Nozawa; Kaori Kanda; Tomohiro Hori; Akihito Nagano; Akira Shimada; Tatsuhiko Miyazaki; Toshiyuki Fukao

doi:10.1097/MPH.0000000000000778

Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

Michio Ozeki, Akifumi Nozawa, Kaori Kanda, Tomohiro Hori, Akihito Nagano, Akira Shimada, Tatsuhiko Miyazaki, Toshiyuki Fukao

University Hospital

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

Abstract

Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

Original language	English
Pages (from-to)	e328-e331
Journal	Journal of Pediatric Hematology/Oncology
Volume	39
Issue number	6
DOIs	https://doi.org/10.1097/MPH.0000000000000778
Publication status	Published - 2017

Keywords

kaposiform hemangioendothelioma (KHE)
mammalian target of rapamycin (mTOR) inhibitor
phosphoinositide-3-kinase (PI3K)
soft tissue tumor
vascular tumor

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/MPH.0000000000000778

Cite this

@article{ac60389fafae4f7b9af730b6c5a22190,

title = "Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma",

abstract = "Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.",

keywords = "kaposiform hemangioendothelioma (KHE), mammalian target of rapamycin (mTOR) inhibitor, phosphoinositide-3-kinase (PI3K), soft tissue tumor, vascular tumor",

author = "Michio Ozeki and Akifumi Nozawa and Kaori Kanda and Tomohiro Hori and Akihito Nagano and Akira Shimada and Tatsuhiko Miyazaki and Toshiyuki Fukao",

year = "2017",

doi = "10.1097/MPH.0000000000000778",

language = "English",

volume = "39",

pages = "e328--e331",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

AU - Ozeki, Michio

AU - Nozawa, Akifumi

AU - Kanda, Kaori

AU - Hori, Tomohiro

AU - Nagano, Akihito

AU - Shimada, Akira

AU - Miyazaki, Tatsuhiko

AU - Fukao, Toshiyuki

PY - 2017

Y1 - 2017

N2 - Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

AB - Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

KW - kaposiform hemangioendothelioma (KHE)

KW - mammalian target of rapamycin (mTOR) inhibitor

KW - phosphoinositide-3-kinase (PI3K)

KW - soft tissue tumor

KW - vascular tumor

UR - http://www.scopus.com/inward/record.url?scp=85010898449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010898449&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000778

DO - 10.1097/MPH.0000000000000778

M3 - Article

C2 - 28121744

AN - SCOPUS:85010898449

SN - 1077-4114

VL - 39

SP - e328-e331

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 6

ER -

Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this